• Test Code:
    5440
  • Department:
  • Test Synonyms:
    Solid Tumor Panel Version 2AKT1AKT2AKT3ALKAPCARARAFARID1AATMATRBAP1BARD1BRAFBRCA1BRCA2BRIP1CASP8CCND1CCNE1CD274CDK12CDKN1BCDKN2ACHK1CHK2CTNNB1DDR2DDX11EGFRERBB2ERBB3ERBB4ERCC2ERCC5ESR1FAM175AFANCAFANCCFANCD2FANCEFANCFFANCGFANCMFGF18FGF19FGF3FGF4FGFR1FGFR2FGFR3FGFR4GNA11GNAQGNASHIST1H3BHRASIDH1IDH2IDO1IDO2INPP4BJAK2KDRKITKRASMAP2K1MAP2K2MAP2K4MAPK1MDC1MDM2MDM4METMLH1MLH3MRE11AMSH2MSH6MTORMUTYHMYCNBNNF1NRASNTRK1NTRK2NTRK3PALB2PDCD1LG2PDGFRAPIK3CAPIK3CBPIK3R1PMS1PMS2POLEPPP2R1APPP6CPTCH1PTENRAC1RAD50RAD51RAD51BRAD51CRAD51DRAD52RAD54LRAF1RASA1RB1RETRICTORRIT1ROS1RPTORSTAG2STAT3STK11TOP1TP53TSC1TSC2XRCC1
  • CPT Code(s):
    81445
Background:

Screening for mutations in oncogenes and tumor suppressor genes is increasingly important in delivering personalized cancer care. The GeneTrails® Solid Tumor Panel is a custom assay that delivers information on clinically informative alterations   among the 124 genes listed below. These genes were selected on the basis of their relevance to current clinical therapies. Alterations may include single nucleotide substitutions, insertions, deletions, and gains or losses in gene copy number. Up to 50 alterations may be reported for any sample, although most will have less than 10. The panel has a lower limit of detection of ~3-5% mutant allele.

This panel can be complemented with the GeneTrails Gene Fusion Panel to screen for actionable kinase gene fusions.  

Recommended Use:  The panel is useful for characterizing solid tumors of all types, providing information that can help optimize treatment with targeted therapeutics, particularly in the setting of advanced disease. The genes listed below are included on the panel. 

AKT1, AKT2, AKT3, ALK, APC, AR, ARAF, ARID1A, ATM, ATR, BAP1, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CASP8, CCND1, CCNE1, CD274, CDK12, CDKN1B, CDKN2A, CHK1, CHK2, CTNNB1, DDR2, DDX11, EGFR, ERBB2, ERBB3, ERBB4, ERCC2, ERCC5, ESR1, FAM175A, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCM, FGF18, FGF19, FGF3, FGF4, FGFR1, FGFR2, FGFR3, FGFR4, GNA11, GNAQ, GNAS, HIST1H3B, HRAS, IDH1, IDH2, IDO1, IDO2, INPP4B, JAK2, KDR, KIT, KRAS, MAP2K1, MAP2K2, MAP2K4, MAPK1, MDC1, MDM2, MDM4, MET, MLH1, MLH3, MRE11A, MSH2, MSH6, MTOR, MUTYH, MYC, NBN, NF1, NRAS,, NTRK1, NTRK2, NTRK3, PALB2, PDCD1LG2, PDGFRA, PIK3CA, PIK3CB, PIK3R1, PMS1, PMS2, POLE, PPP2R1A, PPP6C, PTCH1, PTEN, RAC1, RAD50, RAD51,, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RASA1, RB1, RET, RICTOR, RIT1, ROS1, RPTOR, STAG2, STAT3, STK11, TOP1, TP53, TSC1, TSC2, XRCC1


Methodology:

The Comprehensive Solid Tumor Panel is performed on DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue using next-generation sequencing on an Illumina NextSeq500.  An amplicon-based library is prepared by amplifying input DNA with customized primers followed by modification with adaptors and molecular bar codes. All specimens are reviewed by a pathologist prior to testing to ensure that the submitted material is representative of the target tumor, and that there is adequate tissue for testing.

  • Input DNA: 20 ng
  • Minimum read depth per amplicon:   100

Specimen Requirements:

  • A paraffin block or
  • 10 unstained sections  (4-5 micron)
A REQUISITION FORM MUST ACCOMPANY ALL SAMPLES.  Please include detailed clinical information.

Test Performed (Days):

Twice weekly

Turn Around Time:

14 days

Shipment Sensitivity Requirements:

  • Package and ship specimen to remain cold, but not frozen. 
  • Ship via overnight express, using the FedEx priority overnight label provided. 
  • Contact Client Services at (855) 535-1522 for shipping kits and instructions.

References:

Additional Info:

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More